Meglumine MetrizoateCAS# 7241-11-4 |
- Salmefamol
Catalog No.:BCC1919
CAS No.:18910-65-1
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 7241-11-4 | SDF | Download SDF |
| PubChem ID | 23664 | Appearance | Powder |
| Formula | C19H28I3N3O9 | M.Wt | 823.15 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoic acid;6-(methylamino)hexane-1,2,3,4,5-pentol | ||
| SMILES | CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)N(C)C(=O)C)I.CNCC(C(C(C(CO)O)O)O)O | ||
| Standard InChIKey | TXKOGNLDVKUFSI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H11I3N2O4.C7H17NO5/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-3H3,(H,16,18)(H,20,21);4-13H,2-3H2,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Meglumine Metrizoate Dilution Calculator
Meglumine Metrizoate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2148 mL | 6.0742 mL | 12.1485 mL | 24.2969 mL | 30.3711 mL |
| 5 mM | 0.243 mL | 1.2148 mL | 2.4297 mL | 4.8594 mL | 6.0742 mL |
| 10 mM | 0.1215 mL | 0.6074 mL | 1.2148 mL | 2.4297 mL | 3.0371 mL |
| 50 mM | 0.0243 mL | 0.1215 mL | 0.243 mL | 0.4859 mL | 0.6074 mL |
| 100 mM | 0.0121 mL | 0.0607 mL | 0.1215 mL | 0.243 mL | 0.3037 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6-Methoxydihydrosanguinarine
Catalog No.:BCN7581
CAS No.:72401-54-8
- X-Gal
Catalog No.:BCC1211
CAS No.:7240-90-6
- Oxacillin sodium monohydrate
Catalog No.:BCC4816
CAS No.:7240-38-2
- Yuheinoside
Catalog No.:BCN4279
CAS No.:72396-01-1
- 2,3-Dihydrobellendine
Catalog No.:BCN1896
CAS No.:72362-47-1
- Isobellendine
Catalog No.:BCN1916
CAS No.:72362-45-9
- Licoflavone C
Catalog No.:BCN3256
CAS No.:72357-31-4
- Beta-Carotene
Catalog No.:BCN4965
CAS No.:7235-40-7
- ZJ 43
Catalog No.:BCC2355
CAS No.:723331-20-2
- ZLN024
Catalog No.:BCC5527
CAS No.:723249-01-2
- Rivularine
Catalog No.:BCN2038
CAS No.:723-78-4
- 9-AC
Catalog No.:BCC6867
CAS No.:723-62-6
- Aflatoxin G2
Catalog No.:BCC9215
CAS No.:7241-98-7
- Acifran
Catalog No.:BCC7170
CAS No.:72420-38-3
- Miglitol
Catalog No.:BCC4921
CAS No.:72432-03-2
- Aniracetam
Catalog No.:BCC4219
CAS No.:72432-10-1
- 11-Hydroxytephrosin
Catalog No.:BCN4861
CAS No.:72458-85-6
- Praeruptorin C
Catalog No.:BCN4991
CAS No.:72463-77-5
- Psora 4
Catalog No.:BCC7927
CAS No.:724709-68-6
- STF 31
Catalog No.:BCC7938
CAS No.:724741-75-7
- Pirarubicin
Catalog No.:BCC5092
CAS No.:72496-41-4
- Methyl vanillate glucoside
Catalog No.:BCN4033
CAS No.:72500-11-9
- Felodipine
Catalog No.:BCC4402
CAS No.:72509-76-3
- Lycobetaine
Catalog No.:BCN8313
CAS No.:72510-04-4
Shoulder arthrography with sodium meglumine metrizoate and iopamidol.[Pubmed:2717961]
Skeletal Radiol. 1989;18(2):89-92.
The purpose of this study was to analyze arthrographic imaging of the structures of the shoulder joint when using either sodium Meglumine Metrizoate or iopamidol as a contrast medium. Two hundred and ten patients underwent single-contrast shoulder arthrography. In patients with a full-thickness tear of the rotator cuff, both contrast agents reliably revealed this lesion. However, in patients with a full-thickness rotator cuff tear, the biceps tendon could be demonstrated more readily with iopamidol, which is a non-ionic contrast medium.
Complications in cerebral angiography with iohexol (Omnipaque) and meglumine metrizoate (Isopaque cerebral).[Pubmed:3282185]
Neuroradiology. 1988;30(1):69-72.
The complications of cerebral angiography have been recorded in 1509 examinations with metrizoate (Isopaque Cerebral) and in 1000 examinations with iohexol (Omnipaque). The frequency of complications was 2.0 percent for metrizoate and 1.3 percent for iohexol. Permanent sequelae were seen in 4 patients, 3 in the metrizoate and one in the iohexol group. One of these patients died, probably from thromboembolism. Blood coagulation parameters were studied during the angiography in 22 patients and only minor, probably clinically insignificant changes were found, with no difference between the two contrast media.
Knee arthrography: a comparison of iohexol, ioxaglate sodium meglumine, and metrizoate.[Pubmed:3544035]
Radiology. 1987 Mar;162(3):729-33.
The arthrographic image quality and relative morbidity resulting from use of Omnipaque 300 (iohexol), Hexabrix 320 (ioxaglate sodium meglumine), and Isopaque Coronar 370 (metrizoate) were compared in a prospective double-blind study performed with 120 patients. Radiographs obtained 2, 5, 10, 15, 20, and 25 minutes after injection were judged for diagnostic quality. Relative morbidity was evaluated by the physician during the examination and later by the patient via a questionnaire. Hexabrix demonstrated the best and most persistent diagnostic quality over serial radiographs (P less than .05). Omnipaque caused significantly less postprocedural pain (P less than .05). The other types of discomfort measured did not indicate statistically significant differences in morbidity resulting from the three contrast agents.
Cardiovascular and electrocardiographic effects of iopentol in left ventricular angiography. Comparison of the low-osmolar, non-ionic iopentol (Imagopaque 350) and the hyper-osmolar, ionic metrizoate meglumine-Na-Ca (Isopaque Coronar 370) in patients with coronary heart disease.[Pubmed:9204361]
Eur Radiol. 1997;7 Suppl 4:S156-61.
UNLABELLED: The aim of the study was to evaluate and compare the hemodynamic and electrocardiographic effects following injection of the non-ionic, low-osmolar contrast medium iopentol (Imagopaque 350, Nycomed Imaging AS, Oslo, Norway) and the ionic, hyper-osmolar contrast medium metrizoate meglumine-Na-Ca (Isopaque Coronar 370, Nycomed Imaging AS, Oslo, Norway) when used for left ventricular angiography. The study was performed in a double-blind, randomized manner in 82 patients with severe coronary heart disease. The patients who received iopentol experienced less adverse events and subjective discomfort of lesser intensity than those who received metrizoate (p = 0.0001). Both contrast media induced a biphasic change in left ventricular (LV) systolic pressure, with an initial fall followed by a prolonged rise, but the alterations were statistically significantly more pronounced with metrizoate than with iopentol. The changes in LV end-diastolic pressure (p = 0.023), and LV negative dP/dt (p = 0.002) were significantly more pronounced with metrizoate than with iopentol. Cardiac output and heart rate increased more with metrizoate, while stroke volume was equally increased by both agents. A prolonged increase in the QT-interval, throughout the 10-min observation period, was seen only after injection of metrizoate (p = 0.0006 for comparison between contrast media). CONCLUSION: Iopentol was well tolerated and induced markedly less severe hemodynamic and electrocardiographic alterations than did metrizoate in patients with severe coronary heart disease.
